Detection and quantitation of glutamate carboxypeptidase II in human blood

Prostate

Volumn 74, Issue 7, 2014, Pages 768-780

  Knedlík, Tomáš ^a,b   Navrátil, Václav ^a,b   Vik, Viktor ^c   Pacík, Dalibor ^d   Šácha, Pavel ^a,b   Konvalinka, Jan ^a,b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

glutamate carboxypeptidase II; plasma glutamate carboxypeptidase; prostate cancer; prostate specific membrane antigen; serum marker

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; GLUTAMATE CARBOXYPEPTIDASE II; N ACETYLASPARTYLGLUTAMIC ACID; RECOMBINANT GLUTAMATE CARBOXYPEPTIDASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; IMMUNOPRECIPITATION; INSECT CELL; MALE; MOLECULAR BIOLOGY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOENZYMATIC ASSAY;

GLUTAMATE CARBOXYPEPTIDASE II; PLASMA GLUTAMATE CARBOXYPEPTIDASE; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN; SERUM MARKER;

ADULT; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898782368     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22796     Document Type: Article

References (57)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Israeli RS, Powell CT, Fair WR, Heston WD,. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230.
3. Horoszewicz JS, Kawinski E, Murphy GP,. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-935.
4. Robinson MB, Blakely RD, Couto R, Coyle JT,. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987; 262: 14498-14506.
5. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS,. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150-157.
6. Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J,. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008; 68: 171-182.
7. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP,. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30: 628-636.
8. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP,. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236: 229-238.
9. Chandler CJ, Wang TT, Halsted CH,. Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterization. J Biol Chem 1986; 261: 928-933.
10. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH,. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58: 4055-4060.
11. Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC, McReynolds S, Elder JM, Gilfilen H, Shapiro LH,. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis 2013; 16: 847-860.
12. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH,. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26: 5310-5324.
13. Divyya S, Naushad SM, Murthy PV, Reddy Ch R, Kutala VK,. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Mol Biol Rep 2013; 40: 5541-5550.
14. Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, Lin T, Huang H,. Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 2013; 73: 835-841.
15. Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS,. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000; 45: 350-354.
16. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, Weiner GJ, Bushnell D, Gulfo J,. Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152: 1490-1495.
17. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ,. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-4601.
18. Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PT, Berkman CE,. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett 2012; 22: 3931-3934.
19. Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM,. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 2012; 6: 7752-7762.
20. Taneja SS,. ProstaScint(R) scan: Contemporary use in clinical practice. Rev Urol 2004; 6 (Suppl 10): S19-S28.
21. Troyer JK, Feng Q, Beckett ML, Wright GL Jr., Biochemical characterization and mapping of the 7 E11-C5. 3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995; 1: 29-37.
22. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ,. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721.
23. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M,. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer 2013; 49: 2223-2232.
24. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M,. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002; 53: 9-23.
25. Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH,. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol 2013; 3: 214.
26. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST,. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012; 2012: 973820.
27. Rochon YP, Horoszewicz JS, Boynton AL, Holmes EH, Barren RJ III, Erickson SJ, Kenny GM, Murphy GP,. Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients. Prostate 1994; 25: 219-223.
28. Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, Misrock SL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Gilbaugh J,. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998; 51: 89-97.
29. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ III, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL,. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997; 33: 281-285.
30. Troyer JK, Beckett ML, Wright GL,. Detection and characterization of the prostate-specific membrane antigen (Pmsa) in tissue-extracts and body-fluids. Int J Cancer 1995; 62: 552-558.
31. Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL,. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res 1999; 5: 4034-4040.
32. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr., Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 6029-6033.
33. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, Macfarlane MT, Southwick PC,. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
34. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL,. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413.
35. Moyer VA,. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
36. Gingras R, Richard C, El-Alfy M, Morales CR, Potier M, Pshezhetsky AV,. Purification, cDNA cloning, and expression of a new human blood plasma glutamate carboxypeptidase homologous to N-acetyl-aspartyl-alpha-glutamate carboxypeptidase/prostate-specific membrane antigen. J Biol Chem 1999; 274: 11742-11750.
37. Zajc T, Suban D, Rajkovic J, Dolenc I,. Baculoviral expression and characterization of human recombinant PGCP in the form of an active mature dimer and an inactive precursor protein. Protein Expr Purif 2011; 75: 119-126.
38. Hlouchova K, Barinka C, Klusak V, Sacha P, Mlcochova P, Majer P, Rulisek L, Konvalinka J,. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 2007; 101: 682-696.
39. Tykvart J, Sacha P, Barinka C, Knedlik T, Starkova J, Lubkowski J, Konvalinka J,. Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: Expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 2012; 82: 106-115.
40. Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J,. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002; 80: 477-487.
41. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J,. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007; 144: 1361-1372.
42. Beckett D, Kovaleva E, Schatz PJ,. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 1999; 8: 921-929.
43. Kapust RB, Waugh DS,. Controlled intracellular processing of fusion proteins by TEV protease. Protein Expr Purif 2000; 19: 312-318.
44. Woodward C, Henderson JW Jr., High-speed amino acid analysis (AAA) on 1.8 μm reversed-phase (RP) columns. Wilmington, DE, USA: Agilent Technologies; 2007.
45. Heidenreich PJB, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F,. editors. Guidelines on Prostate Cancer: European Association of Urology, Arnhem 2012.
46. Dolenc I, Mihelic M,. Purification and primary structure determination of human lysosomal dipeptidase. Biol Chem 2003; 384: 317-320.
47. Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG,. GCPII imaging and cancer. Curr Med Chem 2012; 19: 1346-1359.
48. Chang SS,. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6 (Suppl 10): S13-S18.
49. Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Zhang W, Ye L, Zhang M, Ding X, Liu J, Zhu Q, Gao S,. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 2011; 6: 1747-1756.
50. Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, Crainiceau CM, Pomper MG, Rojas C, Pletnikov MV, Calabresi PA, Brandt J, Barker PB, Slusher BS, Kaplin AI,. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc Natl Acad Sci USA 2012; 109: 20101-20106.
51. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Moller JV, Nissen P, Christensen SB, Isaacs JT,. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012; 4: 140ra186.
52. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA,. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 323-329.
53. Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ, Zheng BJ, Qiu SP,. High expression of PSM-E correlated with tumor grade in prostate cancer: A new alternatively spliced variant of prostate-specific membrane antigen. Prostate 2007; 67: 1791-1800.
54. Su SL, Huang IP, Fair WR, Powell CT, Heston WD,. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995; 55: 1441-1443.
55. http://www.uniprot.org/uniprot/?query=ec%3A3.4.17.- +reviewed%3Ayes+AND+organism%3A%22Human+[9606]%22&sort=score; searched January 31, 2014.
56. Collard F, Vertommen D, Constantinescu S, Buts L, Van Schaftingen E,. Molecular identification of beta-citrylglutamate hydrolase as glutamate carboxypeptidase 3. J Biol Chem 2011; 286: 38220-38230.
57. Bromme D, Nallaseth FS, Turk B,. Production and activation of recombinant papain-like cysteine proteases. Methods 2004; 32: 199-206.